Fair insurance guaranty premia in the presence of risk-based capital regulations, stochastic interest rate and catastrophe risk

Article Abstract:

A model for assessing the cost implications for insurance guaranty funds of United States in the event of insolvency of insurers is presented. The model integrates risk-based capital regulations and risks related to interests and catastrophes.

Commodity & service prices, INSURANCE CARRIERS, Asset & Risk Management, Methods, Usage, Insurance industry, Risk management, Suretyship and guaranty, Guarantees, Company pricing policy, Econometric models

---

Deposit insurance and bank interest rate risk: Pricing and regulatory implications

Article Abstract:

This paper evaluates the relationship between the interest rate risk management of banks and its impact on liabilities of a deposit insuring agency like the Federal Deposit Insurance Corp.

Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors, Deposit Interest Regulation, Statistical Data Included, Interest rates, Banking law, Deposit insurance, Deposit banking, Depositories (Banking), United States. Federal Deposit Insurance Corp.

---

Dynamic depositor discipline in US banks

Article Abstract:

The prices and quantity of unsecured deposits in banks of America are analyzed.

Commercial Banks, Clients' funds

Similar abstracts:

• Abstracts: Big pharma wants you. The rise of venture capital and biotechnology in the US and Europe. Term sheet trends in the venture capital market
• Abstracts: The cyclical behavior of optimal bank capital. Capital regulation, heterogeneous monitoring costs, and aggregate loan quality
• Abstracts: EGFR inhibitors square off at ASCO. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
• Abstracts: Reexamining the research exemption. Negotiating the RNAi patent thicket. US courts struggle with new patent infringement standards
• Abstracts: Japan-China merger puts growth in East Asia first. Japanese giants renew interest in industrial biotech. Japanese firms broaden investment focus to early biotech

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.